About us

Background


Dr. Eric van der Veer (CSO & founder) joined the Nephrology department of the Leiden University Medical Center (LUMC) as Post-doc fellow in 2007. During his extensive research period (2007-2015) he focused mainly on RNA-based therapies for kidney targets. Due to his many successful publications, he was asked to become Assistant Professor at Leiden University.

In October 2015, he learned about the devastating clinical complications that the kidney virus (BK-virus) can cause. He connected the dots between the characteristics of antisense oligonucleotides (target-specificity & kidney accumulation) & BK-virus and started Hybridize Therapeutics.

In September 2019, Dr. Eric van der Veer decided to create a spin-off and officially found Hybridize Therapeutics. Currently, Hybridize Therapeutics is in the pre-clinical phase for a therapy against BK-virus and in the early pre-clinical phase for a therapy against JC-virus.

 

Our Team


Eline Vrijland

CEO

Read Bio

Dr. Eric van der Veer

CSO & Founder

Read Bio

Bianca Matthee

COO

Read Bio

Alexander Mentink

Business strategy

Read Bio

Scientific co-founders

Prof. Dr. Anton Jan van Zonneveld

Laboratory Director (LUMC)

Read Bio

Jurriën Prins

Laboratory Supervisor (LUMC)

Read Bio

Strategic Advisory Board

Onno van der Stolpe

CEO Galapagos

Read Bio

Dr. John Maraganore

CEO Alnylam Pharmaceuticals

Read Bio

MD James Shannon

Ex-CMO GlaxoSmithKline

Read Bio

MD Michael Hodges

Drug Development advisor

Read Bio

Dr. Dinko Valerio

Founder Crucell

Read Bio

Daniel de Boer

CEO ProQR

Read Bio

Dr. Andre Hoekema

CBO Galapagos

Read Bio

Scientific Advisory Board

Prof. Dr. Annemieke Aartsma-Rus

Professor Human Genetics, LUMC

Read Bio

Dr. Mariet Feltkamp

Associate Professor, LUMC

Read Bio

Dr. Gerard Platenburg

CIO ProQR

Read Bio

Prof. Dr. Volker Nickeleit

University of North Carolina

Read Bio

Dr. Troels Koch

ex-CTO, Santaris/Roche

Read Bio

Prof. Dr. Jaap Jan Boelens

Chief HSCT Memorial Sloan Kettering

Read Bio

Dr. Ben Laskin

Assistant Prof. Pediatrics Univ. of Pennsylvania

Read Bio

Network and industry expertise of Hybridize Therapeutics


We leverage our extensive network of partners that are leaders in their respective fields.

Patient associations

Health Care Collaborations

Regulatory Support

Investors

Our large clinical network and access to key opinion leaders includes different Nephrology research expert centers worldwide, among which the University of North Carolina at Chapel Hill School of Medicine, University of California in Los Angeles (UCLA), Hannover Medical Center in Germany and the Erasmus Medical Center (Rotterdam) and University of Groningen Medical Center (UMCG) in the Netherlands.